Xenon Pharmaceuticals (XENE)
(Delayed Data from NSDQ)
$37.25 USD
-0.79 (-2.08%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $37.25 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Brokerage Reports
Xenon Pharmaceuticals Inc. [XENE]
Reports for Purchase
Showing records 101 - 120 ( 125 total )
Company: Xenon Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Company: Xenon Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Initiating at Outperform, $23 Target; Well Positioned To Weather A COVID Storm
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Xenon Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
COVID Correction: 6 CNS Programs; 3 Good Partners; $225 MM Cash
Provider: Bloom Burton & Company
Analyst: MARTIN D
Company: Xenon Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Company: Xenon Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Company: Xenon Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Company: Xenon Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Our 12-month target price for XENE increases to $23.00 from $15.00. Maintaining BUY
Provider: Bloom Burton & Company
Analyst: MARTIN D
Company: Xenon Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
2019 TOP IDEAS-Healthcare Sector Review Preview.
Provider: Bloom Burton & Company
Company: Xenon Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Company: Xenon Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Company: Xenon Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Announced that it is expanding its neurology pipeline with the addition of XEN496
Provider: Bloom Burton & Company
Analyst: MARTIN D
Company: Xenon Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Reported phase 1b transcranial magnetic stimulation (TMS) study results at the 13th European Congress
Provider: Bloom Burton & Company
Analyst: MARTIN D
Company: Xenon Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
ATM Share Sales Strengthen Balance Sheet; Reduce Risk
Provider: Bloom Burton & Company
Analyst: MARTIN D
Company: Xenon Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Positive Safety and PD - XEN1101, XEN901 Interim Phase 1 Data
Provider: Bloom Burton & Company
Analyst: MARTIN D
Company: Xenon Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Positive Safety and PD - XEN1101, XEN901 Interim Phase 1 Data
Provider: Bloom Burton & Company
Analyst: MARTIN D
Company: Xenon Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Company: Xenon Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
2018 Top Ideas; Healthcare Sector Review/Preview
Provider: Bloom Burton & Company
Company: Xenon Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Company: Xenon Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
We are reducing our target price to $6.50 (previously $9.50)
Provider: Bloom Burton & Company
Analyst: MARTIN D
Company: Xenon Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Yesterday, Xenon announced that it has acquired worldwide development and commercialization rights to epilepsy drug candidate.
Provider: Bloom Burton & Company
Analyst: MARTIN D